Year: 2020
Type: article
Abstract: Small cell lung cancer (SCLC) is an aggressive subtype of neuroendocrine tumor.It is characterized by a rapid doubling time and early development of metastatic disease.Despite being responsive to initial chemotherapy, most of the patients will have relapse of the disease within a few months.The prognosis of SCLC is dismal with a 5-year survival rate of less than 5%.For that reason, management of SCLC has been an active area of research.The utilization of immunotherapy has provided promising results in treatment of SCLC in the front-line setting.Therefore, utilization of immunotherapy and targeted therapy is being studied in the setting of relapsed/ refractory disease, and currently, different clinical trials are exploring new drugs and further options.In this review, we will explore the latest updates in management of relapsed/refractory SCLC.
Language: English
Topic: Lung Cancer Research Studies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: diamond
OpenAlex ID: W3112621809